Secondary analysis of two prospective lenalidomide maintenance trials in multiple myeloma: lenalidomide-related diarrhoea was associated with raised primary faecal bile acids, reduced gut microbiota diversity and lower predicted bile acid-processing capacity.
Secondary analysis
Miller et al. Lenalidomide-Related Diarrhea in Patients with Multiple Myeloma Is Associated with Gut Microbiota Dysbiosis and Disruption of the Bile Acid Pool